Higher Rates of Delay in Starting Advanced Inflammatory Bowel Disease Therapies Linked to Insurance Delays, Intravenous Infusions, and Lack of Pharmacy Support
In a multicenter study, we found that a delay between prescription and administration of the first dose of an advanced therapy is common, with > 50% of patients having the first dose delayed by > 2 weeks. Delays in starting therapy were significantly more likely if denied by insurance, given by intravenously induction, or at a study site without a dedicated pharmacist.
Authors
- Linda A. Feagins (ORCID: https://orcid.org/0000-0001-7758-3257)
- Jill Gaidos (ORCID: https://orcid.org/0000-0002-1240-1819)
- Hang Nguyen (ORCID: https://orcid.org/0000-0001-6522-381X)
- Faraz Jafri (ORCID: https://orcid.org/0000-0002-6568-8120)
- Kimhouy Tong (ORCID: https://orcid.org/0000-0002-6861-0345)
- Zhouwen Tang (ORCID: https://orcid.org/0000-0001-7600-1008)
- Sara Gottesman (ORCID: https://orcid.org/0009-0006-8703-4538)
- Emily Saweris
- Jonathan Davis (ORCID: https://orcid.org/0000-0002-5164-1241)
- Elizabeth Hernández (ORCID: https://orcid.org/0000-0001-9651-5591)
- Karen Xiao
- Priyanka Jaganathan
Institutions
- Yale University (US)
- The University of Texas at Austin (US)
Publication Details
- Journal
- Clinical and Translational Gastroenterology
- Published
- 2024-12-24
- DOI
- https://doi.org/10.14309/ctg.0000000000000808
- Citations
- 4
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 4.44